NR2F1 and melanoma: Since the majority of patients diagnosed with melanoma are above 66 years of age, and older individuals with melanoma respond worse to BRAFi + MEKi treatment than do younger individuals, we used aged mice to determine whether NR2F1 expression was differentially affected by an aged TME.